Antibiotic Resistance in the Hospital Setting: Advances in Prevention and Management

Faculty

Victoria J. Dudas, PharmD
Independent Clinical Reviewer
Health Sciences Associate Clinical Professor of Pharmacy
Clinical Pharmacist, Department of Pharmaceutical Services
University of California, San Francisco, School of Pharmacy

Robert P. Rapp, PharmD, FCCP
Associate Director of Pharmacy Services
Clinical Pharmacy Specialist for Infectious Diseases
University of Kentucky Medical Center
Professor of Pharmacy
University of Kentucky Colleges of Pharmacy
Professor of Surgery
University of Kentucky College of Medicine

Annie Wong-Beringer, PharmD
Associate Professor of Pharmacy
Vice Chair
Titus Family Department of Clinical Pharmacy and Pharmaceutical Economics Policy
University of Southern California School of Pharmacy

Target Audience

This activity is designed for clinical pharmacists.

Objectives

After completing this activity, participants should be able to:
1. Describe the increasing impact of antibiotic resistance on the incidence and clinical and economic burden of nosocomial infections in the United States;
2. Incorporate safety considerations and potential for resistance, along with coverage, into antibiotic selection for serious infections;
3. Implement IDSA/SHEA guidelines for antimicrobial stewardship into hospital practice;
4. Outline the evidence for use of traditional and new antibiotics for hospitalized patients at risk for resistance and for the prevention and management of resistant infections;
5. Take on a hospital leadership role to maximize infection control and prevention and management of serious infections.

Accreditation

Pharmacy
Princeton CME is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education (ACPE Provider #452) and complies with the Criteria for Quality and Interpretive Guidelines. This activity is approved for 1 contact hour (0.1 CEU) of continuing pharmacy education (UPN 452-000-07-029-H01).

Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by Princeton CME may contact John Savage, Director, Medical Education, North American Center for Continuing Medical Education (NACCME)-Princeton CME, in writing. The Director of Medical Education will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Vice President, Medical Education, NACCME-Princeton CME, may be made for a second level of review.

John Savage
NACCME-Princeton CME
300 Rike Drive, Suite A
Millstone Township, NJ 08535
E-mail: jsavage@naccme.com

Faculty Disclosure

Dr. Rapp serves on the Speaker’s bureau for and is a consultant to Wyeth and Ortho-McNeil.

Dr. Wong-Beringer receives Research Funding from Pfizer (funds paid to University of Virginia).

Dr. Dudas is a consultant to Pfizer and Astellas.

No members of the planning committee have any relevant financial relationships with commercial interests related to this activity.

Princeton CME requires all faculty to inform participants whenever off-label/unapproved uses of drugs or devices are discussed in their presentation. The faculty has disclosed that no off-label/unapproved uses of drugs or devices will be discussed.

Estimated time to complete:  1 hour

Activity Sponsorship